APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia

Author(s): Joel Schmitz, Ioanna Gouni-Berthold*

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 13 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Elevated triglyceride levels (higher than ~1000 mg/dL) are associated with an increased risk for pancreatitis. Apolipoprotein-CIII (apoC-III) plays a key role in the metabolism of triglycerides and triglyceride-rich lipoproteins. Loss of function mutations in the gene encoding apoC-III (APOC3) is associated with low triglyceride levels and a decreased risk for cardiovascular disease (CVD) while overexpression of APOC3 is associated with hypertriglyceridemia. Although many drugs such as fibrates, statins and omega-3 fatty acids modestly decrease triglyceride levels (and apoC-III concentrations), there are many patients who still have severe hypertriglyceridemia and are at increased risk for pancreatitis and potentially for CVD. The antisense oligonucleotide (ASO) against APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIRx and IONIS-ApoCIIIRx) robustly decreases both, apoC-III production and triglyceride concentrations and is being currently evaluated in phase 3 trials. In this narrative review, we present the currently available clinical evidence on the efficacy and safety of volanesorsen for the treatment of hypertriglyceridemia.

Keywords: Antisense oligonucleotides, apolipoprotein C-III, hypertriglyceridemia, IONIS-ApoCIIIRx, ISIS 304801, ISIS-ApoCIIIRx, triglycerides, volanesorsen.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 08 June, 2017
Page: [1567 - 1576]
Pages: 10
DOI: 10.2174/0929867324666170609081612
Price: $65

Article Metrics

PDF: 107
HTML: 19
PRC: 3